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Summary
The efficacy and the mode ofaction of pretransplant transfusion with class I major histocompatibility
complex (MHC)-disparate splenocytes in establishing a stateof peripheral tolerance in adult mice
is analyzed. Adult mice injected intravenously with a critical number of N5 x 10' allogenic
splenocytes accept skin grafts and develop chimerism in the peripheral lymphatic tissues, but
not in thymus and bone marrow. In parallel, a split tolerance evolves: the frequency of class
I MHC-reactive Lyt-2+ cytotoxic T lymphocyte precursor (CTIrp)- and interleukin 2 (IIr2)-
producing T cells falls off in the peripheral lymphoid tissue, but remains unaltered intrathymically.
In particular, high affinity CTLp become clonally undetectable. In vivo generation of tolerant
cells is cyclosporin A resistant, but dependent on recipient L3T4+ T cells. Loss of Lyt-2+ CTIrp-
and IL-2-producing T cell precursors is not due to active suppression, but is caused by clonal
anergy. Donor-derived chimeric cells positively selected 7 d after intravenous transfusion exhibit
in vitro the hallmarks of veto cells, i.e., paralyze CTLp reactive to donor-type class I MHC
alloantigens. We conclude that the peripheral (split) tolerance induced in vivo by pretransplant
transfusion operates because donor-type cells develop in vivo efficiently into "veto cells;' which
in turn induce a state of clonal anergy within antigen-reactive Lyt-2+ T lymphocytes.
A prime aim in transplantation immunology is to define
gentle methods able to convert immune reactivity to
transplantation antigens into a state of immune unrespon-
siveness. This conversion is successful in neonates: introduc-
tion of foreign antigens into a developing immune system
prevents the system from responding further on to these an-
tigens (1, 2). Recent evidence indicates that both in natural
tolerance and in experimentally induced neonatal unrespon-
siveness maturing antigen-reactive thymocytes become either
clonally deleted (3-8) or at least clonally silenced (9-11).
Induction of unresponsiveness in a mature peripheral T
cell pool meets difficulties: receptor occupancy by antigens
primarily induces sensitization rather than tolerization (12-14).
Therefore, most strategies attempt first to reduce the pool
of immunocompetent peripheral T lymphocytes, and there-
after to induce unresponsiveness by exposing the regenerating
(neonatal) immune system to antigen. In the first step, rather
invasive techniques are used, such as whole body (15, 16) or
total lymphoid irradiation (17), systemic application of anti-
proliferative drugs (18, 19), or a combination of either of
these methods.
Evaluation of pretransplant transfusion effects have indi-
cated that intravenous confrontation with allogeneic cells may
induce specific immunosuppression rather than sensitization
(20-28). Independently, Miller, Bevan, and associates (29-36)
pioneered the veto cell concept. Accordingly, unlinked to the
specificity of their own antigen receptor, veto cells paralyze
in vitro the response of T cellsreacting to antigens displayed
by the veto cells (29-36) . Interestingly, upon intravenous trans-
fusion of allogeneic lymphocytes (23-28) or even MHC-
transfected recipient cells (37), recipient mice develop a state
of specific unresponsiveness as if the transfused lymphocytes
were veto cells.
Since intravenous cell transfusion representsa gentle method,
and, in addition, bears the promise to induce unresponsive-
ness in peripheral mature T cells, we have analyzed the efficacy
of this approach in vitro and in vivo. The main findings de-
scribed here are that: (a) injected mice develop a long lasting
chimerism that is paralleled by an unresponsiveness to skin
'Abbreviations used in this paper. CsA, cyclosporin A; CTIrp, CTL
precursor; f, frequency; 11,2 Thp, IIr2-producing T lymphocyte
precursor; LD, limiting dilution; 95% CL, 95% confidence limit; p,
probability of single hit kinetics.
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(i.e., peripheral but not intrathymic CTL precursors (CTLp)t
bearing high affinity tolerogen-reactive TCRs are clonally
silenced); (c) L3T4+ recipient T cells are necessary for toler-
ance induction; and (d) donor-derived lymphocytes isolated
from chimeric recipients display in vitro effective veto
functions.
Materials and Methods
Mice. Breeding pairs of C57B1/6 (B6) (H2KbIAbIEbDb),
B6.C.H26-' (bml) (H2K6'"'IAblEbDb), B6.C.H26m'z (bm12)
(H2KbIAbm'2IEbDb) mice were obtained from The Jackson Labo-
ratory, Bar Harbor, ME. B1l1.BR (H2K'IAkIEkDk) and B10.A
(H2KklAkIEkDd) mice were purchased from OLAC, Blackthorn,
UK. CB17 (H2K`IAdIEdDd) mice were bred in the animal facility
ofthe Ulm University. The mica: were used at an age of 8-12 wk.
Reagents.
￿
Human rI1r2 was a kind gift from Eurocetus, Am-
sterdam, The Netherlands (batch no. LP-370B). Con A was ob-
tained from Pharmacia Fine Chemicals, Uppsala, Sweden. Cyclospo-
rine A (CsA) was generously provided by Dr. Borel, Sandoz AG,
Basel, Switzerland. CsA (1 mg) was dissolved in 100 I4l C2H50H
and 20 j.1 Tween 80 (Sigma Chemical Co., Munich, FRG). A stock
solution (1 mg/ml) was prepared by adding 880,ul PBS. Mice re-
ceived 20 mg/kg body weight daily intraperitoneally. Selected rabbit
low-tox complement was purchased from Cederlane, Hornby,
Canada. Rat IgG was purchased from Sigma Chemical Co. PE-
coupled streptavidin was from Becton Dickinson & Co., Heidel-
berg, FRG.
mAbs. FITC-conjugated anti-Lyt-2 antibodies and biotin-
coupled anti-L3T4 and antiThy-1.2 antibodieswere obtained from
Becton Dickinson & Co., and used for cell sorter analyses. Hybrid-
omas GK-1.5 (anti-L3T4, a kind gift from Dr. Fitch, University
of Chicago), 53-6.72 (anti-Lyt-2; American Type Culture Collec-
tion,Rockville,MD), HO-13-4 (antiThy-1.2; American Type Cul-
ture Collection), and 34-4-20S (anti-H2Dd; American Type Cul-
ture Collection) were grown as ascites. mAbs were purified from
ascites fluid using standard methods (38). Anti-Dd antibodies were
coupled with FITC to a FITC/protein ratioof 2 using the method
of Goding (39) .
Cell Staining and Cytofluorometry.
￿
For analyses, 2-5 x 101 cells
were incubated with the respective mAb for 30 min at 4°C. There-
after, the cells were washed twice with PBS, and, when necessary,
a second incubation with PE-coupled streptavidin was performed.
Subsequently, the cells were fixed with paraformaldehyde. 1-3 x
104 cells were analyzed with an Epics V cell sorter (Coulter Im-
munology, Hialeah, FL) . Cells were gated on forward angle light
scatter, and the green (FITC) and red (PE) fluorescence wasrecorded.
For cell sorting, 10' cells were stained and sorted according their
fluorescence intensity. The purity ofthe sorted population exceeded
98% when reanalyzed.
Complement Lysis.
￿
Splenocytes (10'/ml) were incubated for 30
min on ice with the respective antibody. After washing twice with
PBS, the cells were incubated at 37°C with a 1:10 dilution ofrabbit
low-tox complement (Cederlane) for 30 min. This procedure was
repeated twice. Cell sorter analyses revealed that the efficacy ofcom-
plement lysis was >98%.
Cell Preparation.
￿
Thymi and spleens were removed aseptically
and then teased. The cell suspension was freed from erythrocytes
by a briefincubation in NH4C1. Spleen cells were always passed
over a nylon wool column.
Limiting Dilution Cultures.
￿
Limiting dilution (LD) cultures were
720
￿
Veto Cell-Mediated Tolerance In Vivo
set up as detailed elsewhere (40). Briefly, replicates (n = 16) of
graded numbers ofresponder cells were cultured together with 3 x
105 irradiated (12 Gy) stimulator cells in 200 F1 of medium. Cul-
ture medium (Click/RPMI; Biochrom, Berlin, FRG) was sup-
plemented with 10% heat-inactivated FCS (Biochrom), 10 mM
Hepes buffer, 2 mM glutamine, 5 x 10-5 M mercaptoethanol, 1
,ug/ml indomethacin, and antibiotics. Note that LD cultures for
the estimation of CTLp frequencies were supplemented with 20
U/ml rllr2, while in LD cultures for the determination of IL2
producer T cells, 10% WEHI-3 and 10% P388-Dl supernatant
(41) was added.
AssayforIL2 Activity and Cytotoxicity.
￿
IL2 activity in the super-
natant of LD cultures was assayed after restimulation with 2 x
105 irradiated (100 Gy) (41) stimulator cells using a colorime-
tric assay (41, 42). The "Cr release assay was performed as de-
scribed (40).
Statistical Analyses.
￿
In LD analyses, all cultures generating cy-
totoxicityor containing IIr2 exceeding the mean values plus three
times the SD ofcultures containing only stimulatorcells were con-
sidered positive. Calculation offrequencies (f), 95% confidencelimits
of the frequencies (95% CL), and probabilities of single hit ki-
netics (p) were performed as described (40).
Skin Grafting.
￿
Mice were anesthetized with pentobarbital (0.6
mg/10 g mouse weight). Tail skin grafts (5 x 5 mm) were then
transplanted onto the left chest wall according to the method of
Brent et al. (43). Skin grafts were scored for viability three times
a week.
Results
Transfusion with MHC Class I-Disparate Splenocytes Alters
TCellReactivity. Upon intravenous injection of spleen cells
from bml mice into adult B6 recipients, the in vivo and in
vitro reactivity of recipient mice changes dramatically. The
majority of B6 recipients receiving 5 x 107 allogeneic bm1
spleen cells tolerated bml skin grafts for >4 wk. As detailed
in Fig. 1 A, the cell number injected was critical for the in-
duction of unresponsiveness in vivo. In vitro, the frequency
of anti-bml-reactive CTLp in the recipient spleen dropped
from 1:513 (control) to 1:10,500 within 8 d (Fig. 1 B). This
frequency reduction compares well with the loss of antigen-
reactive CTLp observed in neonatally induced tolerance to
class I MHC antigens (9-11). Reduction ofanti-bml-reactive
CTLp occurred rapidly within 24 h, peaked at day 10-20,
lasted for at least 4 wk (Fig. 1 C), and was antigen specific,
since the frequency of third party-reactive CTIrp remained
unaltered (data not shown). Fig. 1 D further details that the
selective reduction of anti-bml-reactive T cells was not
confined to CTLp, but also included anti-bm-l-reactive II,
2-producing T cells. Using cell sorter-purified Lyt-2+ T
cells from recipient mice, we found that it is this subset that
developed specific unresponsiveness (vide infra) . Essentially
similar results were obtained in the B10.A -" B10.BR com-
bination (H-21)d difference).
Not Thymic, butPeripheral CTLp Become Affected.
￿
Next,
the frequency of anti-bml-reactive purified thymic Lyt-2+
L3T4 - T cells was compared with that of peripheral T cells
7 d after intravenous injection of 5 x 107 bml spleen cells
into B6 recipients. While in peripheral T cells, the frequency
of anti-bml-reactive CTLp was reduced to -18% ofthe con-Pt
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trol (Fig . 2 A), the number of thymic CTLp remained
unaffected (Fig . 2 B) .
We also analyzed whether the few remaining anti-bml-
reactive CTLp in the peripheral T cell pool of tolerant B6
mice could be scored as high affinity or low affinity CTLp.
To this, LD cultures were set up and clonally developing CTL
colonies (probability for clonality >80%) were assayed for
lytic activity towards bml targets in the presence or absence
of blocking anti-Lyt-2 mAb (44) . As detailed in Fig . 3 A,
7 of 30 (23%) colonies from splenic T cells of normal B6
mice were able to lyse bml targets in the presence of Lyt-2
mAb, and thus have to be scored as T cells bearing high affinity
120
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c
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Figure 1 .
￿
(A) Skin graft survival after injection of allogeneic spleen cells. B6 mice (n = 10 per group) were injected intravenously with the
indicated numbers of allogeneic (burl) spleen cells . 1 d later, the mice were grafted with bml tail skin grafts. Starting at day 7, the grafts were
inspected three times a week. (B) Limiting dilution analysis of splenocytes from tolerant mice. B6 mice were injected intravenously with 5 x
107 bml spleen cells . 8 d later, nylon wool-nonadherent splenic cells were prepared and incubated with bml stimulator cells under limiting dilu-
tion conditions . After 7 d, cells of individual cultures were tested for lytic activity against bml blast target cells . The fraction of negative repli-
cate cultures is plotted against the number of responder cells seeded . lln = frequency, (n-n) = 95% confidence limit of the frequency, p -
probability of single hit kinetics) . (C and D) Kinetics of frequency reduction . B6 mice were injected with 5 x 107 bmi spleen cells. After
different time points, the frequency of burl-reactive CTITp (C) or IIJ2 TLp (D) of splenic T cells was assessed in LD analyses. The frequency
reduction is displayed as a fraction of the frequency of normal control mice .
TCRs (44). On the other hand, no high affinity anti-bml-
reactive CTLp were found in the spleen of tolerant B6 mice.
(Fig . 3 B) .
In Vivo Tolerance Induction ofLyt-2 + T Cells Is L3T4+ T
CellDependent, butCsA Resistant. In vivo injection of L3T4-,
Lyt-2-, or even Thy-1.2-depleted splenic bml cells into B6
recipients was almost equally effective in causing a selective
loss of anti-bml-reactiveCTLp (Fig. 4) . On the other hand,
recipient L3T4 + T cells were necessary for in vivo induc-
tion of tolerance. Thus, B6 mice injected intraperitoneally
with 2 mg of anti-L3T4 mAb to deplete their L3T4+ T
cells (45-47) retained their ability to reject bml skin graftsB
splenic T cells
responder cell number
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Figure 2.
￿
Frequency analysis of splenic T and mature thymorytes
in tolerant mice. Splenic T cells (A) and cell sorter-purified Lyt-
2'L3T4- mature thyinic T cells (B) from normal (+) and tolerized
(') (7 d after intravenous injection of bml spleen cells) B6 mice were
stimulated under LD conditions with bml stimulator cells. After 7 d,
the LD cultures were tested for lyric activity against bm1 blast target
cells. The fraction of negative cultures is plotted against the number
of responder cells seeded.
(Fig. 5), and the frequency of anti-bml-reactive CTirp was
altered only marginally (Table 1). These results cannot be ex-
plained by the assumption that donor L3T4+ T cells in the
inoculum were critical for tolerance induction, since L3T4+
T cell-depleted splenocytes are effective in inducing CTIrp
reduction (Fig. 4) . Thus, these results imply that recipient
L3T4+ T cells are essential for tolerance induction.
CsA inhibits not only lymphokine transcription and secre-
tion in T cells (48), but also TCR-mediated signals down-
722
￿
Veto Cell-Mediated Tolerance In Vivo
stream from IIT2R expression during primary activation of
resting T cells (40, 49, 50). Since induction of tolerance is
antigen specific at the clonal level, and thus likely to be chan-
neled via the TCR/T3 complex, we anticipated that CsA
would interfere with tolerance induction in the model system
studied here. However, the results given in Table 2 clearly
demonstrate that the mechanism of tolerance induction by
transfusion with class I MHC-incompatible spleen cells in
adult mice is CsA resistant.
Both DonorandRecipient T CellsAre Clonallx Silenced, and
DonorLymphocytes Veto theReactivity towards TheirOwn Class
1 MHC Antigens. Using an FITC-labeled H-2Da mAb, we
analyzed the state ofchimerism in the B10.A - B10.BR mouse
combination. While in bone marrow or thymus no donor
cells were found (Table 3), significant numbers (3-9%) of
Dd-positive B10.A donor cells were detected for up to 20 d
in the spleen ofrecipient B10.BRmice (Table 3, Fig. 6). About
50-60% of these donor cells expressed the Thy-1.2 T cell
marker (Table 3).
Upon depletion, by cell sorting, of donor cells from the
spleen of tolerant mice, the recipient B10.BR T cells remained
unresponsive towards donor-type stimulator cells (Table 4).
Thus, unresponsiveness of recipient T cells is not due to ac-
tive suppression by donor T cells, but represents a state of
unresponsiveness due to either functional or clonal deletion.
This type of result also extends to donor-derived B10.A lym-
phocytes from tolerized mice. As detailed in Table 5, B10.A
cells positively selected from chimeric (tolerant) mice con-
tained X10-fold reduced frequencies of antirecipient (Dk)-
reactive CTITp.
Even though donor lymphocytes were found to be tolerant,
i.e., clonally depleted for antirecipient (anti-Dk)-reactive
CTIrp, the very same cells efficiently suppressed the primary
activation of CTIrp with reactivity to donor class I MHC
antigens; i.e., expressed veto cell function. For example, when
B10.A (donor) cells that were positively selected from spleens
of $10.BR (recipient) mice 7 d after intravenous injection
of B10.A spleen cells were subsequently mixed at a ratio of
1:1 with normal B10.$R splenic responder cells, and there-
aftercocultured at limiting dilution with 3 x 105 irradiated
B10.A stimulator cells, a biphasic LD curve is obtained. At
high cell input (>1,000 veto cells), the frequency of anti-
B10.Areactive CTIrp is effectively reduced (Fig. 7 A; Table
6, biphasic curve II), while at low cell numbers (<1,000 cells),
the frequency remained unaltered (Fig. 7 A, biphasic curve
I). Thus, as few as 1,000 veto cells are sufficient to block in
LD cultures the primary activation of naive B10.BR CTIrp
reactive to MHC antigens also expressed on veto cells. This
suppression was antigen specific, since the reactivityto third-
party antigens was not affected (Fig. 7 B; Table 6). Donor-
derived B10.A cells from chimeric mice appear to be enriched
for veto function, because B10.A cells from normal mice failed
to suppress anti-B10.A responses in vitro (Table 6).
Discussion
The results described here will be discussed in the context
of pretransplant transfusion effects (20-28), the veto cell%-ILL
60
20
10
i.v. L3T4-
i.v. Lyt2-
i.v. Thyl .2-
control
i.v.
i.v. irr.
1-10
B6
bml + Lyt2
bml
10
rt
0 10 20 30 40 50 60 %-rr.1.
￿
0 10 20
0 200 400 600 600 1000
CTL-p/10"6
PBS i.v.
-- bm1 i.v.
. . . anti-L3T4
+ bm1 i.v.
- rat
11.
+
bm1 v.
16 20
days p.L
Figure 5.
￿
L3T4+ T cell depletion prevents tolerance induction. B6
mice were first injected intraperitoneally with 2 mg anti-L3T4 anti-
bodies or 2 mg rat Ig. 2 d later, the mice received intravenously 5 x
107 bml spleen cells and were subsequently grafted with bml skin.
Anti-L3T4 and rat Ig injection was continued twice a week. Starting
at day 7, grafts were inspected three times a week.
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High affinity CTL be-
come tolerized. A LD analysis of
control (A) and tolerized (day 7) (B)
splenic T cells was set up. After
7 d, the LD cultures were split and
tested against bml blast target cells
in the presence or absence of
blocking anti-Lyt-2 antibodies. The
lytic reactivity of individual colonies
displaying a high probability
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Figure 4.
￿
L3T4- , Lyt-2- , and Thy-1.2 - splenic
bml cells induce selective reduction of CTIrp. B6
mice were injected with 5 x 107 bml splenocytes
or splenocytes depleted for Thy-1.2+, Lyt-2+, or
L3T4+ cells, or irradiated bml splenocytes. After
1200
￿
7 d, the number of bml-reactive CTIrp was
enumerated.
phenomenon first described by Miller and associates (29-36),
and the concept of peripheral tolerance as opposed to toler-
ance induced by intrathymic clonal deletion ofantigen-reactive
T lymphocytes (1-11). We show here that after intravenous
injection of a critical number of allogeneic class I MHC-
incompatible donor lymphocytes, recipient mice accept donor
type skin grafts for >30 d. This state of unresponsiveness
is paralleled by a state of chimerism in peripheral lymphatic
tissues, but not in bone marrow or thymus. This split
chimerism correlates with a state of split tolerance. Thus,
the frequency of anti-donor-reactive CTIrp as well as 11'2-
producing T cells falls offdramatically in the peripheral lym-
phatic organs, reaching, after4-5 d, 5-10%of control values.
Yet, in the thymus, the frequency of donor-reactive CTLp
remains unaltered. Both anti-donor-reactive recipient CTLp
as well as anti-recipient-reactive donor CTIrp are clonally
silenced. Interestingly, it is the subset ofCTLp bearing high
affinity TCRs that becomes functionally deleted. In vitro,
donor-typelymphocytes, positivelyselected from tolerant chi-
meric mice, bear the hallmarks of veto cells, in that theyB6 mice were injected intraperitoneally with 2 mg anti-L3T4 antibodies, 2 mg rat Ig, or PBS twice a week. As indicated, some mice were further
injected intravenously with 5 x 107 bml spleen cells. The frequency of bml-reactive CTILp of splenic T cells was determined 7 d later.
Table 2.
￿
Effect of CsA during the In Vivo Induction of
Tolerance
B10.BR mice were injected intravenously with 5 x 107 B10.A
splenocytes. Some mice (n = 2) received daily 20 mg/kg body
weight CsA intraperitoneally. After 7 d, the number of B10.A
(tolerogen)- or bm12 (third-party)-reactive CTL-p was determined.
The percentages of the frequencies of control animals (n = 3) are
given.
specifically block primary activation of CTIrp reactive to-
wards the veto cells' own class I MHC alloantigens. Since
in vivo the donor (veto) cells do not affect the repertoire of
maturing thymocytes, we conclude that transfusion of adult
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Table 3.
￿
Donor Cell Chimerism in Tolerant Mice
B10.BR mice were injected with B10.A spleen cells. After 7 d, splenocytes were depleted by cell sorting of donor-derived cells, and, subse-
quently, the frequency of CTL-p was determined with reactivity to either the tolerogen (B10.A cells) or third-party cells (bm12).
B10.BR mice were injected with B10.A spleen cells. After 7 d, the
splenocytes, thymocytes, lymph node cells, and bone marrow cells
were prepared and stained with a monoclonal FITC-conjugated anti-
Dd antibody and biotin-coupled anti-Thy-1 .2 antibodies. After fur-
ther incubation with streptavidin-PE, the cells were analyzed for red
and green fluorescence.
mice with class I MHC-incompatible lymphocytes leads to
a stateofperipheral (split) toleranceandthusallows chimerism
to be maintained. Why do donor and recipient T cells not
reject each other? Peripheral tolerance appears not to be due
CsA
Percent of control
B10.A (tolerogen)
frequency
bm12 (third party)
Tissue Control
Percent staining cells
mice Intravenously injected mice
Spleen 0.5 9.2 (Thy-1 .2+, 65 .3%)
- 16 87 Thymus 0.4 0.4
- 23 109 Mesent .
+ 7 85 lymph node 0.2 8.4 (Thy-1 .2+, 46 .9%)
+ 20 97 Bone marrow 0.4 0.6
Table 1. L3T4* T Cell Depletion Prevents the Induction of Tolerance to Class I MHC Alloantigens
CTL-p
Anti-L3T4 Rat Ig Anti-bml
injection injection tolerization 1/f 95% CL p
No No No 681 429-1,103 0.55
No No Yes 12,884 7,780-37,464 0.83
Yes No No 488 352-795 0.99
Yes No Yes 1,641 1,182-2,681 0.98
No Yes No 381 275-681 0.95
No Yes Yes 9,045 5,561-24,224 0.40
Table 4. Frequency Analysis of Donor Cell-Depleted Host Lymphocytes
Intravenous Donor cell B10.A (tolerogen) bm12 (third party)
tolerization depletion
(day 0) (day 7) l/F 95% CL p 1/F 95% CL p
No No 2,979 2,085-4,982 0.91 1,327 965-2,098 0.99
Yes No >74,435 1,289 888-2,345 0.64
Yes Yes 36,381 17,017-74,421 0.94 765 505-1,582 0.1515
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Figure 6 .
￿
Donor cell chimerism in tolerized mice. B10.BR mice
were injected with 5 x 107 B10.A splenocytes. After different time
points, spleen cells from tolerized mice were stained with an FITC-
coupled anti-Dd antibody and analyzed with an Epics V cell sorter.
Staining of control B10.BR spleen cells was <0.5% .
Table 5 .
￿
Frequency Analysis ofDonor-Derived Lymphocytes
from Chimeric (Tolerant) Mice
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B10.BR mice were tolerized by intravenous injection of B10.A
spleen cells . After 7 d, donor-derived cells were positively selected
by cell sorting, and subsequently, the frequency of antirecipient
(B10.BR)-reactive CTL-p was enumerated and compared with that
of B10.A cells of control mice.
to active suppression, but due to clonal paralysis of antigen-
reactive Lyt-2+ CTIrp- and 11,2-producing Lyt-2+ T cells .
Since donor lymphocytes exhibit clonal anergy to recipient
class IMHC antigens, yet express in vitro remarkably efficient
veto functions, we believe that the reciprocal peripheral toler-
ance in the adult chimeric mice is caused, and maintained,
by veto activity of donor and recipient cells.
Deletion of recipient L3T4+ T cells before pretransplant
transfusion abrogates the ability of the recipient to be toler-
ized (Fig. 5 ; Table 1) . Although establishment of tolerance
to class IMHC antigens by pretransplant transfusion meets
difficulties if the transfused allogeneic lymphocytes in addi-
tion are class IIMHC incompatible (26, 27, unpublished data),
a problem that is overcome by systemic application of anti-
L3T4 mAb (27), our data, in addition, imply that recipient
L3T4+ cells are essential for the in vivo development of veto
B10.A
responder cell mrnber
BB
Figure 7.
￿
Donor-derived cells specifically suppress antidonor re-
sponses . B10.BR mice were injected intravenously with B10.A spleen
cells. After 7 d, the frequency of splenic T cells from control and
tolerized mice against the tolerogen (B10.A) and third-party MHC
antigens (B6) was tested . A fraction of tolerized spleen cells was fur-
ther stained with anti Dd antibodies, and donor-derived cells were
positively selected with a cell sorter. These cells were mixed 1 :1 with
splenic T cells from normal nontolerized B10.BR mice and, subse-
quently, a LD analysis was performed . (A) (') Control mouse, f -
1:1,018 (1:711-1,796), p - 0.87 ; (+) tolerized mouse f - 1:7,750
(1:5,128-1:15,846) p - 0.99 ; (O) 1 :1 mixture of donor-derived cells
and control B10.BR cells . (----) Linear part I of the biphasic LD
analysis; frequency estimate, 1:976 ; (. . . . . . .) linear part II of the
biphasic LD analysis; frequency estimate, 1:3,138 . (B) (') Control
mouse, f - 1:1,110 (1:815-1:1,739), p - 0.97 ; (+) tolerized mouse
f = 1:1,302 (1:950-1:2,071), p - 0.99; (O) 1 :1 mixture f = 1:572
(1:416-1:915), p - 0.96 .
Responder
cells
Stimulator
cells 1/F
CTL-p
95% CL p
B10.A e >
(control) B10.BR 762 545-1,265 0.94 d
Donor-derived g
B10.A B10.BR 8,843 5,454-18,688 0.99 s
SB10.BR mice were injected with B10.A spleen cells. After 7 d, donor-derived cells were positively selected via cell sorting. Splenic T cells from
B10.BR mice (line 1) were admixed with spleen cells from B10.A mice (line 2) or B10.A donor-derived cells (line 3) at a ratio of 1:1. These
cell populations and splenocytes from tolerized mice (line 4) were subjected to a LD analysis. Mixing of donor-derived B10.A cells to normal
B10.BR splenic responder cells resulted in a biphasic LD curve when the reactivity against B10.A stimulator cells was analyzed. Biphasic parts I
and II give the frequency estimates of the linear parts of the respective segment of the LD analysis.
cell-dependent peripheral tolerance. Recipient L3T4+ T
cells might interact with MHC classII-expressing donor veto
cells directly, or might support the activation of veto func-
tions by actively participating in the in vivo response to class
I MHC antigens via lymphokine secretion. Assuming the
latter, why then is the generation of veto cell activity resis-
tant to the effects of cyclosporine A known to block not only
lymphokine transcription and secretion,but also primary ac-
tivation of resting T cells? In ongoing experiments, we are
analyzing whether systemic application of defined recombinant
lymphokines such as IIr2 can restore the ability of L3T4+
T cell-deficient adult mice to become tolerized by pretrans-
plant transfusion.
We show that pretransplant transfusion results in a state
of split tolerance, i.e., high affinity TCRs bearing periph-
eral, but not thymic, CTIrp become functionally deleted. This
contrasts to neonatally induced tolerance, in which thymic
and bone marrow chimerism develops (9) . Since in the adult
mouse chimerism induced by pretransplant transfusion fades
with time, an effect that is paralleled by the reappearance of
tolerogen-reactive CTIrp and IL2-producing T lymphocyte
precursor (Ilr2 TIrp) (Fig. 1, C and D), we presently inves-
tigate conditions to induce a stable, long-lasting chimerism
by bone marrow grafting as well.
In the model system ofneonatal tolerance,removal ofdonor-
derived cells revealed the existence of anti-donor-reactive T
cells (10, 11, 51) . No evidence for active suppression was ob-
tained in the model system detailed here (Table 4). Yet, un-
like naive donor type cells, donor type cells selected 7 d after
transfusion efficiently vetoed primary CTL responses in vitro
(Fig. 7; Table 6), as if they were enriched for veto cells. Obvi-
ously, these cells are the candidates for the cells that adop-
tively transferred tolerance in vivo, as recently reported by
Martin and Miller (28) .
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Since there is evidence that in vitro veto cells do not clonally
delete antigen-reactive T cells, but rather induce paralysis that
can be overcome within time (unpublished data), we antici-
pate the continuous existence of clonally silenced CTIrp in
adult mice transfused with class I MHC-incompatible splenic
cells. The availability of TCRtransgenic mice (7, 8) will allow
us to experimentally approach this question. There is already
evidence that neonatal tolerization for reactivity to Mls an-
tigens phenotypically abolishes anti-Mls reactivity in vitro
and in vivo without clonally deleting the respectiveVii-bearing
lymphocytes (52).
Even though there are numerous indications that pretrans-
plant transfusion can induce specific immunosuppression rather
than sensitization (20-28), the results presented here provide
compelling evidence that pretransplant transfusion-induced
peripheral tolerance to class I MHC antigens is associated
with the in vivo activation and selection ofremarkablyefficient
veto cells. Opposing thymic deletion of antigen-reactive T
cells as a basis for negative selection of maturing T lympho-
cytes (4-8), veto cells operating in peripheral tolerance clonally
appear to silence mature Lyt-2 * T cells. If so, then the in
vivo induction and maintenance of tolerance to MHC class
I antigens by veto cells might represent a paradigm for nat-
ural peripheral tolerance to self-antigens not present in the
thymus. Accordingly, veto cells control the reactivity towards
endogenously produced proteins and peptides, and might thus
be further involved in immunoregulatory networks. On the
other hand, pretransplant transfusion represents a gentle pro-
cedure to "open the window" of unresponsiveness in adult
mice for the establishment of conditions for inducing a stable
chimerism that then would imply an indefinitive stateoftrans-
plantation tolerance against foreign MHC alloantigens.
Table 6. Donor(BIO.A}Derived Cells,
Responder cells
but Not
1/F
Normal B10.A Cells, Specifically
B10.A (tolerogen)
95% CL
Suppress
p
Anti-B10.A
1/F
Responses In Vitro
bm12 (third party)
95% CL p
B10.BR 1,682 1,174-2,966 0.94 948 687-1,529 0.59
B10.BR + B10.A (1:1) 1,833 1,327-2,963 0.38 362 254-575 0.79
B10.BR + donor-derived B10.A
cells (1:1)
biphasic part 1 1,619 899 619-1,639 0.85
biphasic part 11 6,953
B10.BR tolerized 7,662 4,946-17,000 0.97 704 508-1,149 0.79References
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